PDF herunterladen
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2021; 81(01): 46-60
DOI: 10.1055/a-1247-5271
GebFra Science
Review

COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding

COVID-19-Behandlung: Arzneimittelsicherheit vor und während der Schwangerschaft sowie in der Stillzeit
Marcelo Borges Cavalcante
1   Department of Obstetrics and Gynecology, University of Fortaleza (UNIFOR), Fortaleza-CE, Brazil
2   CONCEPTUS – Reproductive Medicine, Fortaleza-CE, Brazil
,
Candice Torres de Melo Bezerra Cavalcante
3   Department of Pediatrics, University of Fortaleza (UNIFOR), Fortaleza-CE, Brazil
,
Ana Catherine Sampaio Braga
1   Department of Obstetrics and Gynecology, University of Fortaleza (UNIFOR), Fortaleza-CE, Brazil
,
Dennyse Araújo Andrade
1   Department of Obstetrics and Gynecology, University of Fortaleza (UNIFOR), Fortaleza-CE, Brazil
,
Mariana Albuquerque Montenegro
1   Department of Obstetrics and Gynecology, University of Fortaleza (UNIFOR), Fortaleza-CE, Brazil
,
Paula Andrade Neiva Santos
1   Department of Obstetrics and Gynecology, University of Fortaleza (UNIFOR), Fortaleza-CE, Brazil
,
Paula Vitória Pereira Motoyama
1   Department of Obstetrics and Gynecology, University of Fortaleza (UNIFOR), Fortaleza-CE, Brazil
,
Marcelo Gondim Rocha
1   Department of Obstetrics and Gynecology, University of Fortaleza (UNIFOR), Fortaleza-CE, Brazil
2   CONCEPTUS – Reproductive Medicine, Fortaleza-CE, Brazil
,
Luciana Azôr Dib
1   Department of Obstetrics and Gynecology, University of Fortaleza (UNIFOR), Fortaleza-CE, Brazil
2   CONCEPTUS – Reproductive Medicine, Fortaleza-CE, Brazil
,
Edward Araujo Júnior
4   Department of Obstetrics, Paulista School of Medicine – Federal University of São Paulo (EPM-UNIFESP), São Paulo-SP, Brazil
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

In December 2019, a new viral respiratory infection known as coronavirus disease 2019 (COVID-19) was first diagnosed in the city of Wuhan, China. COVID-19 quickly spread across the world, leading the World Health Organization to declare it a pandemic on March 11, 2020. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a similar virus to those involved in other epidemics such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Epidemiological studies have shown that COVID-19 frequently affects young adults of reproductive age and that the elderly and patients with chronic disease have high mortality rates. Little is known about the impact of COVID-19 on pregnancy and breastfeeding. Most COVID-19 cases present with mild flu-like symptoms and only require treatment with symptomatic relief medications, whereas other cases with COVID-19 require treatment in an intensive care unit. There is currently no specific effective treatment for COVID-19. A large number of drugs are being used to fight infection by SARS-CoV-2. Experience with this therapeutic arsenal has been gained over the years in the treatment of other viral, autoimmune, parasitic, and bacterial diseases. Importantly, the search for an effective treatment for COVID-19 cannot expose pregnant women infected with SARS-CoV-2 to the potential teratogenic risks of these drugs. Therefore, it is necessary to determine and understand the safety of anti-COVID-19 therapies prior to conception and during pregnancy and breastfeeding.

Zusammenfassung

Im Dezember 2019 wurde erstmals eine neue virale Atemwegserkrankung, die den Namen Coronavirus-Erkrankung 2019 (COVID-19) bekam, in der chinesischen Stadt Wuhan diagnostiziert. COVID-19 verbreitete sich rasch über die ganze Welt, was die Weltgesundheitsorganisation veranlasste, am 11. März 2020 eine Pandemie auszurufen. Die neuartige Erkrankung wird von einem Virus aus der Familie der Coronaviridae hervorgerufen und wird SARS-CoV-2 (severe acute respiratory syndrome coronovirus type 2) genannt. SARS-CoV-2 trägt ähnliche Merkmale wie Viren, die bei anderen Epidemien als Erreger auftraten, z. B. SARS-CoV (severe acute respiratory syndrome coronavirus) und MERS-CoV (Middle East respiratory syndrome coronavirus). Epidemiologische Studien haben gezeigt, dass COVID-19 oft junge Erwachsene im fortpflanzungsfähigen Alter befällt und dass die Sterberaten bei älteren Menschen und Menschen mit chronischen Erkrankungen hoch sind. Über die Auswirkungen von COVID-19 während der Schwangerschaft und in der Stillzeit ist wenig bekannt. Die meisten Fälle mit COVID-19 haben milde grippeähnliche Symptome und benötigen Medikamente nur, um die Symptome zu bekämpfen. Andere Patienten hingegen müssen auf der Intensivstation behandelt werden. Es gibt derzeit keine spezifische, effektive Behandlung gegen COVID-19. Es werden aber eine ganze Reihe von Medikamenten eingesetzt, um gegen die Infektion mit SARS-CoV-2 zu kämpfen. Die Erfahrungen mit diesem therapeutischen Arsenal wurden über Jahrzehnte hinweg durch ihren Einsatz gegen andere virale, autoimmune, parasitäre und bakterielle Erkrankungen gesammelt. Wichtig ist, dass bei der Suche nach einer effektiven Behandlung gegen COVID-19 keine schwangeren Frauen mit SARS-CoV-2 den möglichen teratogenen Risiken dieser Therapeutika ausgesetzt werden. Es ist daher nötig, die Sicherheit von Anti-COVID-19-Therapien präkonzeptionell sowie während der Schwangerschaft und in der Stillzeit zu bestimmen.

Key words

COVID-19 - SARS-CoV-2 - antiviral - pregnancy - breastfeeding

Schlüsselwörter

COVID-19 - SARS-CoV-2 - antiviral - Schwangerschaft - Stillen


Publikationsverlauf

Eingereicht: 19. Juni 2020

Angenommen nach Revision: 25. August 2020

Artikel online veröffentlicht:
19. Januar 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Guan WJ, Ni ZY, Hu Y. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382: 1708-1720
    CrossrefPubMedGoogle Scholar
  • 2 World Health Organization (WHO). Coronavirus disease (COVID-19) dashboard. Accessed June 04, 2020 at: https://covid19.who.int/
    PubMedGoogle Scholar
  • 3 Sutton D, Fuchs K, DʼAlton M. et al. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. N Engl J Med 2020; DOI: 10.1056/NEJMc2009316.
    CrossrefPubMedGoogle Scholar
  • 4 Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant 2020; 39: 405-407
    CrossrefPubMedGoogle Scholar
  • 5 Ye Z, Rochwerg B, Wang Y. et al. Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline. CMAJ 2020; DOI: 10.1503/cmaj.200648.
    CrossrefPubMedGoogle Scholar
  • 6 Ye Z, Wang Y, Colunga-Lozano LE. et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. CMAJ 2020; DOI: 10.1503/cmaj.200645.
    CrossrefPubMedGoogle Scholar
  • 7 Tang N, Bai H, Chen X. et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18: 1094-1099
    CrossrefPubMedGoogle Scholar
  • 8 Wu R, Wang L, Kuo HD. et al. An Update on Current Therapeutic Drugs Treating COVID-19. Curr Pharmacol Rep 2020; DOI: 10.1007/s40495-020-00216-7.
    CrossrefPubMedGoogle Scholar
  • 9 Sanders JM, Monogue ML, Jodlowski TZ. et al. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020; DOI: 10.1001/jama.2020.6019.
    CrossrefPubMedGoogle Scholar
  • 10 Brucker MC, King TL. The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule. J Midwifery Womens Health 2017; 62: 308-316
    CrossrefPubMedGoogle Scholar
  • 11 Wilmer E, Chai S, Kroumpouzos G. Drug safety: Pregnancy rating classifications and controversies. Clin Dermatol 2016; 34: 401-409
    CrossrefPubMedGoogle Scholar
  • 12 Stumpfe FM, Titzmann A, Schneider MO. et al. SARS-CoV-2 Infection in Pregnancy – a Review of the Current Literature and Possible Impact on Maternal and Neonatal Outcome. Geburtshilfe Frauenheilkd 2020; 80: 380-390
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 13 Ellington S, Strid P, Tong VT. et al. Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status – United States, January 22 – June 7, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 769-775
    CrossrefPubMedGoogle Scholar
  • 14 Smith DD, Pippen JL, Adesomo AA. et al. Exclusion of Pregnant Women from Clinical Trials during the Coronavirus Disease 2019 Pandemic: A Review of International Registries. Am J Perinatol 2020; DOI: 10.1055/s-0040-1712103.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 15 Tripathy S, Dassarma B, Roy S. et al. A review on possible modes of actions of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. Int J Antimicrob Agents 2020; 56: 106028 doi:10.1016/j.ijantimicag.2020.106028
    CrossrefPubMedGoogle Scholar
  • 16 Wang M, Cao R, Zhang L. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269-271
    CrossrefPubMedGoogle Scholar
  • 17 Mehra MR, Desai SS, Ruschitzka F. et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020; DOI: 10.1016/S0140-6736(20)31180-6.
    CrossrefPubMedGoogle Scholar
  • 18 Apotex. Product monograph (Hydroxychloroquine Sulfate Tablets). Accessed June 04, 2020 at: https://pdf.hres.ca/dpd_pm/00054599.pdf
    PubMedGoogle Scholar
  • 19 Peterson EA, Lynton J, Bernard A. et al. Rheumatologic Medication Use During Pregnancy. Obstet Gynecol 2020; 135: 1161-1176
    CrossrefPubMedGoogle Scholar
  • 20 Birru Talabi M, Clowse MEB. Antirheumatic medications in pregnancy and breastfeeding. Curr Opin Rheumatol 2020; 32: 238-246
    CrossrefPubMedGoogle Scholar
  • 21 Sheahan TP, Sims AC, Graham RL. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9: eaal3653
    CrossrefPubMedGoogle Scholar
  • 22 de Wit E, Feldmann F, Cronin J. et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A 2020; 117: 6771-6776
    CrossrefPubMedGoogle Scholar
  • 23 Grein J, Ohmagari N, Shin D. et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020; DOI: 10.1056/NEJMoa2007016.
    CrossrefPubMedGoogle Scholar
  • 24 Di Lorenzo G, Di Trolio R, Kozlakidis Z. et al. COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature. Crit Rev Oncol Hematol 2020; 152: 102991 doi:10.1016/j.critrevonc.2020.102991
    CrossrefPubMedGoogle Scholar
  • 25 Beigel JH, Tomashek KM, Dodd LE. et al. Remdesivir for the Treatment of Covid-19 – Preliminary Report. N Engl J Med 2020; DOI: 10.1056/NEJMoa2007764.
    CrossrefPubMedGoogle Scholar
  • 26 Food and Drug Administration (FDA). Fact sheet for health care providers. Emergency use authorization (EUA) of remdesivir (gs-5734™). Accessed June 04, 2020 at: https://www.fda.gov/media/137566/download
    PubMedGoogle Scholar
  • 27 Dashraath P, Wong JLJ, Lim MXK. et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol 2020; DOI: 10.1016/j.ajog.2020.03.021.
    CrossrefPubMedGoogle Scholar
  • 28 Roberts SS, Martinez M, Covington DL. et al. Lopinavir/ritonavir in pregnancy. J Acquir Immune Defic Syndr 2009; 51: 456-461
    CrossrefPubMedGoogle Scholar
  • 29 Chu CM, Cheng VC, Hung IF. et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59: 252-256
    CrossrefPubMedGoogle Scholar
  • 30 Hung IF, Lung KC, Tso EY. et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020; DOI: 10.1016/s0140-6736(20)31042-4.
    CrossrefPubMedGoogle Scholar
  • 31 Sheahan TP, Sims AC, Leist SR. et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11: 222
    CrossrefPubMedGoogle Scholar
  • 32 Zumla A, Chan JF, Azhar EI. et al. Coronaviruses – drug discovery and therapeutic options. Nat Rev Drug Discov 2016; 15: 327-347
    CrossrefPubMedGoogle Scholar
  • 33 Gasmi A, Noor S, Tippairote T. et al. Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. Clin Immunol 2020; 215: 108409
    CrossrefPubMedGoogle Scholar
  • 34 Cao B, Wang Y, Wen D. et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020; 382: 1787-1799
    CrossrefPubMedGoogle Scholar
  • 35 McKee DL, Sternberg A, Stange U. et al. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res 2020; 157: 104859
    CrossrefPubMedGoogle Scholar
  • 36 Tookey PA, Thorne C, van Wyk J. et al. Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland. BMC Infect Dis 2016; 16: 65
    CrossrefPubMedGoogle Scholar
  • 37 Gandhi M, Mwesigwa J, Aweeka F. et al. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr 2013; 63: 578-584
    CrossrefPubMedGoogle Scholar
  • 38 Blaising J, Polyak SJ, Pécheur E-I. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res 2014; 107: 84-94
    CrossrefPubMedGoogle Scholar
  • 39 Haviernik J, Štefánik M, Fojtíková M. et al. Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses. Viruses 2018; 10: 184
    CrossrefPubMedGoogle Scholar
  • 40 Lian N, Xie H, Lin S. et al. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect 2020; DOI: 10.1016/j.cmi.2020.04.026.
    CrossrefPubMedGoogle Scholar
  • 41 Deng L, Li C, Zeng Q. et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect 2020; DOI: 10.1016/j.jinf.2020.03.002.
    CrossrefPubMedGoogle Scholar
  • 42 Zhu Z, Lu Z, Xu T. et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect 2020; DOI: 10.1016/j.jinf.2020.03.060.
    CrossrefPubMedGoogle Scholar
  • 43 Srinivas P, Sacha G, Koval C. Antivirals for COVID-19. Cleve Clin J Med 2020; DOI: 10.3949/ccjm.87a.ccc030.
    CrossrefPubMedGoogle Scholar
  • 44 Takashita E, Ejima M, Ogawa R. et al. Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. Antiviral Res 2016; 132: 170-177
    CrossrefPubMedGoogle Scholar
  • 45 Furuta Y, Gowen BB, Takahashi K. et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013; 100: 446-454
    CrossrefPubMedGoogle Scholar
  • 46 Chen C, Zhang Y, Huang J. et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv 2020; DOI: 10.1101/2020.03.17.20037432.
    CrossrefPubMedGoogle Scholar
  • 47 Cai Q, Yang M, Liu D. et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing) 2020; DOI: 10.1016/j.eng.2020.03.007.
    CrossrefPubMedGoogle Scholar
  • 48 (LactMed) Drugs and Lactation Database. Bethesda (MD): National Library of Medicine (US); 2006. Favipiravir. Accessed June 04, 2020 at: https://www.ncbi.nlm.nih.gov/books/NBK556878/
    PubMedGoogle Scholar
  • 49 Jamieson DJ, Honein MA, Rasmussen SA. et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 2009; 374: 451-458
    CrossrefPubMedGoogle Scholar
  • 50 Tan Q, Jin Y. Ostavimir is ineffective against COVID-19: in silico assessment, in vitro and retrospective study. medRxiv 2020; DOI: 10.1101/2020.05.15.20102392.
    CrossrefPubMedGoogle Scholar
  • 51 Peng F, Tu L, Yan Y. et al. Management and Treatment of COVID-19: The Chinese Experience. Can J Cardiol 2020; DOI: 10.1016/j.cjca.2020.04.010.
    CrossrefPubMedGoogle Scholar
  • 52 Phua J, Weng L, Ling L. et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med 2020; 8: 506-517
    CrossrefPubMedGoogle Scholar
  • 53 Ding Q, Lu P, Fan Y. et al. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol 2020; DOI: 10.1002/jmv.25781.
    CrossrefPubMedGoogle Scholar
  • 54 Donner B, Niranjan V, Hoffmann G. Safety of oseltamivir in pregnancy: a review of preclinical and clinical data. Drug Saf 2010; 33: 631-642
    CrossrefPubMedGoogle Scholar
  • 55 Anderson PO. Breastfeeding and Respiratory Antivirals: Coronavirus and Influenza. Breastfeed Med 2020; 15: 128
    CrossrefPubMedGoogle Scholar
  • 56 Damle B, Vourvahis M, Wang E. et al. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19. Clin Pharmacol Ther 2020; DOI: 10.1002/cpt.1857.
    CrossrefPubMedGoogle Scholar
  • 57 Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ. et al. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther 2014; 143: 225-245
    CrossrefPubMedGoogle Scholar
  • 58 Zimmermann P, Ziesenitz VC, Curtis N. et al. The Immunomodulatory Effects of Macrolides-A Systematic Review of the Underlying Mechanisms. Front Immunol 2018; 9: 302
    CrossrefPubMedGoogle Scholar
  • 59 Gbinigie K, Frie K. Should azithromycin be used to treat COVID-19? A rapid review. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101094.
    CrossrefPubMedGoogle Scholar
  • 60 Bookstaver PB, Bland CM, Griffin B. et al. A Review of Antibiotic Use in Pregnancy. Pharmacotherapy 2015; 35: 1052-1062
    CrossrefPubMedGoogle Scholar
  • 61 Zhang W, Zhao Y, Zhang F. et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol 2020; 214: 108393
    CrossrefPubMedGoogle Scholar
  • 62 Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 2011; 335: 2-13
    CrossrefPubMedGoogle Scholar
  • 63 Veronese N, Demurtas J, Yang L. et al. Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature. Frontiers in Medicine 2020; 7: 170
    CrossrefPubMedGoogle Scholar
  • 64 Li X, Ma X. Acute respiratory failure in COVID-19: is it “typical” ARDS?. Crit Care 2020; 24: 198
    CrossrefPubMedGoogle Scholar
  • 65 Bandoli G, Palmsten K, Forbess Smith CJ. et al. A Review of Systemic Corticosteroid Use in Pregnancy and the Risk of Select Pregnancy and Birth Outcomes. Rheum Dis Clin North Am 2017; 43: 489-502
    CrossrefPubMedGoogle Scholar
  • 66 Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35: 7s-14s
    CrossrefPubMedGoogle Scholar
  • 67 Alfano G, Fontana F, Mori G. et al. Antiviral activity of sirolimus in an HIV-positive kidney transplant recipient. Int J STD AIDS 2019; 30: 919-922
    CrossrefPubMedGoogle Scholar
  • 68 Kindrachuk J, Ork B, Hart BJ. et al. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother 2015; 59: 1088-1099
    CrossrefPubMedGoogle Scholar
  • 69 Sargiacomo C, Sotgia F, Lisanti MP. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?. Aging 2020; 12: 6511-6517
    CrossrefPubMedGoogle Scholar
  • 70 Food and Drug Administration (FDA). Rapamune (sirolimus) oral solution and tablets prescribing information. Accessed June 04, 2020 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021083s048lbl.pdf
    PubMedGoogle Scholar
  • 71 Armenti VT, Daller JA, Constantinescu S. et al. Report from the National Transplantation Pregnancy Registry: outcomes of pregnancy after transplantation. Clin Transpl 2006; 57-70
    PubMedGoogle Scholar
  • 72 Luo P, Liu Y, Qiu L. et al. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol 2020; DOI: 10.1002/jmv.25801.
    CrossrefPubMedGoogle Scholar
  • 73 Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19?. J Transl Med 2020; 18: 164
    CrossrefPubMedGoogle Scholar
  • 74 Hoeltzenbein M, Beck E, Rajwanshi R. et al. Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data. Semin Arthritis Rheum 2016; 46: 238-245
    CrossrefPubMedGoogle Scholar
  • 75 Lei J, Vermillion MS, Jia B. et al. IL-1 receptor antagonist therapy mitigates placental dysfunction and perinatal injury following Zika virus infection. JCI Insight 2019; 4: e122678
    CrossrefPubMedGoogle Scholar
  • 76 Hill-Batorski L, Halfmann P, Marzi A. et al. Loss of Interleukin 1 Receptor Antagonist Enhances Susceptibility to Ebola Virus Infection. J Infect Dis 2015; 212 (Suppl. 02) S329-S335
    CrossrefPubMedGoogle Scholar
  • 77 Cavalli G, De Luca G, Campochiaro C. et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2020; 2: e325-e331
    CrossrefPubMedGoogle Scholar
  • 78 Nanjan MJ, Mohammed M, Prashantha Kumar BR. et al. Thiazolidinediones as antidiabetic agents: A critical review. Bioorg Chem 2018; 77: 548-567
    CrossrefPubMedGoogle Scholar
  • 79 Davidson MA, Mattison DR, Azoulay L. et al. Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. Crit Rev Toxicol 2018; 48: 52-108
    CrossrefPubMedGoogle Scholar
  • 80 Carboni E, Carta AR, Carboni E. Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?. Med Hypotheses 2020; 140: 109776
    CrossrefPubMedGoogle Scholar
  • 81 Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med 2020; 8: e21
    CrossrefPubMedGoogle Scholar
  • 82 Chan LY, Yeung JH, Lau TK. Placental transfer of rosiglitazone in the first trimester of human pregnancy. Fertil Steril 2005; 83: 955-958
    CrossrefPubMedGoogle Scholar
  • 83 Takeda Canada Inc.. Product monograph (pioglitazone hydrochloride). Accessed June 04, 2020 at: https://www.takeda.com/siteassets/en-ca/home/what-we-do/our-medicines/product-monographs/actos/actos-pm-18jan2018-clean_en.pdf
    PubMedGoogle Scholar
  • 84 Deftereos SG, Siasos G, Giannopoulos G. et al. The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design. Hellenic J Cardiol 2020; DOI: 10.1016/j.hjc.2020.03.002.
    CrossrefPubMedGoogle Scholar
  • 85 Leung YY, Yao Hui LL, Kraus VB. Colchicine–Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum 2015; 45: 341-350
    CrossrefPubMedGoogle Scholar
  • 86 Indraratna PL, Virk S, Gurram D. et al. Use of colchicine in pregnancy: a systematic review and meta-analysis. Rheumatology (Oxford) 2018; 57: 382-387
    CrossrefPubMedGoogle Scholar
  • 87 Gómez-Meda BC, Bañales-Martínez LR, Zamora-Perez AL. et al. Micronucleated Erythrocytes in Peripheral Blood from Neonate Rats Exposed by Breastfeeding to Cyclophosphamide, Colchicine, or Cytosine-Arabinoside. Biomed Res Int 2016; 2016: 9161648
    PubMedGoogle Scholar
  • 88 Laing R, Gillan V, Devaney E. Ivermectin – Old Drug, New Tricks?. Trends Parasitol 2017; 33: 463-472
    CrossrefPubMedGoogle Scholar
  • 89 Caly L, Druce JD, Catton MG. et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020; 178: 104787
    CrossrefPubMedGoogle Scholar
  • 90 Merck Sharp & Dohme Corp. Product monograph (Ivermectin). Accessed June 04, 2020 at: https://www.merck.com/product/usa/pi_circulars/s/stromectol/stromectol_pi.pdf
    PubMedGoogle Scholar
  • 91 Chen W, Mook RA, Premont RT. et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal 2018; 41: 89-96
    CrossrefPubMedGoogle Scholar
  • 92 Xu J, Shi P-Y, Li H. et al. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. ACS Infect Dis 2020; 6: 909-915
    CrossrefPubMedGoogle Scholar
  • 93 Pindiprolu SKSS, Pindiprolu SH. Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19. Med Hypotheses 2020; 140: 109765
    CrossrefPubMedGoogle Scholar
  • 94 Cook GC. Use of antiprotozoan and anthelmintic drugs during pregnancy: side-effects and contra-indications. J Infect 1992; 25: 1-9
    CrossrefPubMedGoogle Scholar
  • 95 Marano G, Vaglio S, Pupella S. et al. Convalescent plasma: new evidence for an old therapeutic tool?. Blood Transfus 2016; 14: 152-157
    PubMedGoogle Scholar
  • 96 Rojas M, Rodríguez Y, Monsalve DM. et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev 2020; 19: 102554 doi:10.1016/j.autrev.2020.102554
    CrossrefPubMedGoogle Scholar
  • 97 Rajendran K, Krishnasamy N, Rangarajan J. et al. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol 2020; DOI: 10.1002/jmv.25961.
    CrossrefPubMedGoogle Scholar
  • 98 Brown BL, McCullough J. Treatment for emerging viruses: Convalescent plasma and COVID-19. Transfus Apher Sci 2020; 59: 102790 doi:10.1016/j.transci.2020.102790
    CrossrefPubMedGoogle Scholar
  • 99 Zeng QL, Yu ZJ, Gou JJ. et al. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients. J Infect Dis 2020; DOI: 10.1093/infdis/jiaa228.
    CrossrefPubMedGoogle Scholar
  • 100 Grisolia G, Franchini M, Glingani C. et al. Convalescent plasma for coronavirus disease 2019 in pregnancy: a case report and review. Am J Obstet Gynecol MFM 2020; 2: 100174 doi:10.1016/j.ajogmf.2020.100174
    CrossrefPubMedGoogle Scholar
  • 101 van Griensven J, Edwards T, de Lamballerie X. et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med 2016; 374: 33-42
    CrossrefPubMedGoogle Scholar
  • 102 Mulloy B, Hogwood J, Gray E. et al. Pharmacology of Heparin and Related Drugs. Pharmacol Rev 2016; 68: 76-141
    CrossrefPubMedGoogle Scholar
  • 103 Mycroft-West CJ, Su D, Pagani I. et al. Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the surface protein (spike) S1 receptor binding domain with heparin. bioRxiv 2020; DOI: 10.1101/2020.04.28.066761.
    CrossrefPubMedGoogle Scholar
  • 104 Hemilä H. Vitamin C and Infections. Nutrients 2017; 9: 339
    CrossrefPubMedGoogle Scholar
  • 105 Fowler AA, Truwit JD, Hite RD. et al. Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. JAMA 2019; 322: 1261-1270
    CrossrefPubMedGoogle Scholar
  • 106 Kim WY, Jo EJ, Eom JS. et al. Combined vitamin C, hydrocortisone, and thiamine therapy for patients with severe pneumonia who were admitted to the intensive care unit: Propensity score-based analysis of a before-after cohort study. J Crit Care 2018; 47: 211-218
    CrossrefPubMedGoogle Scholar
  • 107 Rumbold A, Crowther CA. Vitamin C supplementation in pregnancy. Cochrane Database Syst Rev 2005; (02) CD004072 DOI: 10.1002/14651858.CD004072.pub2.
    CrossrefPubMedGoogle Scholar
  • 108 Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol 2014; 21: 319-329
    CrossrefPubMedGoogle Scholar
  • 109 Cantorna MT, Snyder L, Lin YD. et al. Vitamin D and 1,25(OH)2D regulation of T cells. Nutrients 2015; 7: 3011-3021
    CrossrefPubMedGoogle Scholar
  • 110 Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281
    CrossrefPubMedGoogle Scholar
  • 111 Agarwal S, Kovilam O, Agrawal DK. Vitamin D and its impact on maternal-fetal outcomes in pregnancy: A critical review. Crit Rev Food Sci Nutr 2018; 58: 755-769
    CrossrefPubMedGoogle Scholar
  • 112 DʼAvolio A, Avataneo V, Manca A. et al. 25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2. Nutrients 2020; 12: 1359
    CrossrefPubMedGoogle Scholar
  • 113 Daneshkhah A, Agrawal V, Eshein A. et al. The Possible Role of Vitamin D in Suppressing Cytokine Storm and Associated Mortality in COVID-19 Patients. medRxiv 2020; DOI: 10.1101/2020.04.08.20058578.
    CrossrefPubMedGoogle Scholar
  • 114 Baltaci AK, Mogulkoc R, Baltaci SB. Review: The role of zinc in the endocrine system. Pak J Pharm Sci 2019; 32: 231-239
    PubMedGoogle Scholar
  • 115 Wessels I, Maywald M, Rink L. Zinc as a Gatekeeper of Immune Function. Nutrients 2017; 9: 1286
    CrossrefPubMedGoogle Scholar
  • 116 Skalny AV, Rink L, Ajsuvakova OP. et al. Zinc and respiratory tract infections: Perspectives for COVID-19 (Review). Int J Mol Med 2020; DOI: 10.3892/ijmm.2020.4575.
    CrossrefPubMedGoogle Scholar
  • 117 Wilson RL, Grieger JA, Bianco-Miotto T. et al. Association between Maternal Zinc Status, Dietary Zinc Intake and Pregnancy Complications: A Systematic Review. Nutrients 2016; 8: 641
    CrossrefPubMedGoogle Scholar
  • 118 Ota E, Mori R, Middleton P. et al. Zinc supplementation for improving pregnancy and infant outcome. Cochrane Database Syst Rev 2015; 2015 (02) CD000230
    PubMedGoogle Scholar
  • 119 Tchkonia T, Zhu Y, van Deursen J. et al. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 2013; 123: 966-972
    CrossrefPubMedGoogle Scholar
  • 120 Chapagain P. Potential Role of Cellular Senescence on Coronavirus Infections. Preprints 2020; 2020040532 doi:10.20944/preprints202004.0532.v1
    CrossrefPubMedGoogle Scholar
  • 121 Kim JA, Seong RK, Shin OS. Enhanced Viral Replication by Cellular Replicative Senescence. Immune Netw 2016; 16: 286-295
    CrossrefPubMedGoogle Scholar
  • 122 Frescas D, Roux CM, Aygun-Sunar S. et al. Senescent cells expose and secrete an oxidized form of membrane-bound vimentin as revealed by a natural polyreactive antibody. Proc Natl Acad Sci U S A 2017; 114: E1668-E1677
    CrossrefPubMedGoogle Scholar
  • 123 Johnson JR, Makaji E, Ho S. et al. Effect of maternal raspberry leaf consumption in rats on pregnancy outcome and the fertility of the female offspring. Reprod Sci 2009; 16: 605-609
    CrossrefPubMedGoogle Scholar
  • 124 [Anonym] Quercetin. IARC Monogr Eval Carcinog Risks Hum 1999; 73: 497-515
    PubMedGoogle Scholar